×
Zimmer Biomet reported third-quarter 2026 net sales of $2.063 billion , up 3.1% on a reported basis and 3.7% in constant currency. Adjusted diluted earnings per share (EPS) came in at $1.90 , roughly in line with the prior-year quarter and modestly above analyst consensus estimates.
STERIS reported adjusted earnings per share (EPS) of $2.94 for its fiscal 2027 second quarter, beating the consensus estimate of $2.68 by roughly 9.8%. Revenue reached $1.59 billion, ahead of the $1.56 billion consensus and up about 8.8% from the same period a year earlier.
Edwards Lifesciences reported third-quarter 2026 net sales of $1.72 billion, up about 10% from $1.55 billion a year earlier and ahead of the $1.68 billion consensus estimate. Adjusted earnings per share (EPS) rose 19% year over year to $0.80, beating analyst expectations of $0.74 by $0.06.
The central target of $37 is the arithmetic mean of five verified analyst price targets, which average roughly $36.60. Those five targets range widely, from $32 (Stifel) to $45 (Leerink Partners), reflecting genuine disagreement about valuation.
OrthoPediatrics (KIDS) is a pediatric orthopedic device specialist posting double-digit revenue growth and rising guidance, while DENTSPLY Sirona (XRAY) is a global dental equipment and consumables maker working through a turnaround marked by softer growth and leadership transitions. Tickeron AI Verdict: KIDS. Trend consistency, stronger relative momentum, and an improving profitability and cash-flow trajectory currently favor OrthoPediatrics over DENTSPLY Sirona in this head-to-head stock comparison.
CNMD climbed roughly 12.8% over the last 30 days, from about $47.33 on October 5, 2026 to approximately $53.38 in early November. The advance was amplified by renewed media reports that CONMED is weighing strategic alternatives, including a potential sale, following private-equity interest.
2026 guidance signals disciplined scaling: Management expects roughly $890 million in revenue (up about 17%) and approximately $134 million in adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization), implying continued margin expansion toward a 15% operating margin. Robotics is a pivotal near-term catalyst: A controlled rollout of the Valence navigation and robotics platform is planned for 2026, with more meaningful revenue contribution expected as the year progresses.
Commercialization is the central catalyst: Phaos Technology Holdings (Cayman) Limited must convert its patented microsphere-based super-resolution imaging technology into recurring, higher-volume sales across manufacturing, biomedical, and research end markets. Strategic positioning hinges on differentiation: The company's ability to visualize beyond the traditional 200-nanometer optical diffraction limit at commercially viable working distances underpins its niche, but the franchise remains early-stage with a lean operating footprint.
The central target used here is $2.00, but it is not an analyst-derived figure: Phaos Technology Holdings (Cayman) Limited has no meaningful sell-side coverage or published consensus, so a fallback target based on public technical discussion was used instead. At a recent verified price near $1.08, reaching $2.00 would require a gain of roughly 85% — a very large move for any security.
POAS shares fell roughly 60% over the last 30 days, sliding from a closing price of about $2.17 in early October to approximately $0.87. The decline extends a sustained downtrend since Phaos Technology's $4.00-per-share initial public offering in November 2025.
ALMR dropped -12.41% during regular market hours, sliding from a previous close of $30.22 to roughly $26.47. The decline followed a Nov 3 after-hours Q3 report that beat estimates and raised full-year revenue guidance but flagged flat sequential Q4 growth as TAP revenue is guided lower, alongside a Form 4 showing >10% holder Qiming sold roughly 188,000 shares.
INFU edged up +1.72% during regular market hours, from Tuesday's $12.80 close to $13.02. The gain is a mild rebound after Tuesday's -7.51% selloff on the delayed Q3 earnings announcement; results released today slightly missed estimates (EPS $0.12 vs. $0.13; revenue $37.3M vs. $37.39M).
CeriBell (CBLL) fell -2.26%, from a previous close of $28.27 to $27.63, during regular trading on November 4, paring a much steeper early premarket drop. The decline follows Q3 results released after the November 3 close: a wider-than-expected GAAP loss (-$0.55 vs -$0.51 consensus) overshadowed a slight revenue beat ($29.3M) and a raised lower end of 2026 revenue guidance ($115M-$117M), triggering an initial premarket selloff that later faded.
RxSight reported third-quarter 2026 revenue of $24.6 million, down 19% from $30.3 million a year earlier and below the roughly $27.2 million consensus estimate. Adjusted earnings per share (EPS) came in at a loss of $0.21, narrower than the consensus estimate of a $0.29 loss, driven in part by tighter cost control.
Standard BioTools is expected to report third quarter 2026 results in early November, with consensus estimates pointing to revenue near $18.8 million and a loss of roughly $0.02 per share . The report arrives as the company works toward closing its all-stock combination with privately held Treeline Biosciences , targeted to complete before year-end 2026.
InfuSystem Holdings postponed its third quarter 2026 earnings release, which had been scheduled for November 3, 2026, citing the need for additional time to complete its quarter-end financial reporting. The delay centers on an accounting evaluation of approximately $4.2 million in ERP (enterprise resource planning) implementation costs, which the company has expensed as incurred since July 2024.
NeuroPace, Inc. (NPCE) is scheduled to report third-quarter 2026 results after the market close on Thursday, November 12, 2026. Analysts expect a narrower loss of roughly $0.09 per share on revenue near $27.1 million, according to available consensus data.
SS Innovations International is scheduled to report third-quarter 2026 results for the quarter ended September 30, 2026, with consensus earnings per share (EPS) near -$0.01 and revenue expectations of roughly $14 million to $15 million. The company follows a standard calendar fiscal year, so its third quarter covers the July-through-September 2026 period.
AdaptHealth reported third quarter 2026 net revenue from continuing operations of $745.6 million , up 10.9% year over year and above the roughly $726 million consensus estimate. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) came in at $141.9 million , ahead of the approximately $130 million consensus expectation.
Total revenue reached $29.3 million , up roughly 30% year over year and modestly ahead of the consensus estimate of about $29.2 million. GAAP (generally accepted accounting principles) net loss per share was $0.55 , wider than the roughly $0.50 loss analysts had projected.
Previous
16 of 31
Next